The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models
Resistance to microtubule targeting agents (MTA) represents a major drawback in successful cancer therapy with MTAs. Here we investigated the combined treatment modality of the novel MTA BAL101553 in combination with radiotherapy in paclitaxel and epothilone-resistant tumor models.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Ashish Sharma, Angela Broggini-Tenzer, Van Vuong, Alessandra Messikommer, Katarzyna J. Nytko, Matthias Guckenberger, Felix Bachmann, Heidi A. Lane, Martin Pruschy Tags: Original article Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Medical Training Application Service | Radiology